argenx entered Q3 2026 earnings with a volatile share price and a reputation as a high‑growth autoimmune specialist that investors either love for its pipeline or worry about for its spending. The firm then printed roughly US$1.75b in quarterly sales and US$506m in net income, yet the stock closed at €783.4 on 22 October after recent months of choppy trading.
The expectation gap sits squarely on profitability. The trailing net profit margin of 31.7% now tracks well below last year’s 41.6%. The immediate question for you is simple: are you paying for past earnings strength, or for a business that is accepting leaner margins to pursue future launches?
Love argenx’s scale and autoimmune focus but uneasy about a thinner 31.7% margin and the spending behind it? Compare this setup with a curated list of solid balance sheet and fundamentals stocks (203 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): US$1,751 million vs. US$1,151.338 million (up about 52%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): US$506 million vs. US$344.258 million (up about 47%)
- Basic EPS (Q3 2026 vs Q3 2025): US$8.07 vs. US$5.61 (up about 44%)
- Trailing 12-Month Net Profit Margin (latest vs prior year): 31.7% vs. 41.6% (margin compressed by about 10 percentage points)
Ask Charlie what argenx isn’t saying about five 2027 launches.
argenx bull case: platform milestones vs profit squeeze
The bullish pitch is that argenx is turning VYVGART into a broad autoimmune platform, not a single indication story.
"👉 Strategy: expand a single mechanism across multiple autoimmune indications"
Q3 shows that thesis being executed. VYVGART net sales reached US$1.7b with strong contribution from both MG and CIDP, and ALKIVIA delivered a Phase 3 win in autoimmune myositis with an IMNM filing planned by year end. Ten clinical molecules and progress with FB102 in celiac disease indicate that the mechanism centric plan is broadening beyond one drug and one pathway.
argenx bear case: concentration and spend under the microscope
The bear worry is that argenx leans too hard on one product while costs rise and pipeline risk stays high.
"👉 Insight: • Single-product concentration risk, but with label expansion opportunity"
Current figures still point to dependence. VYVGART supplies the bulk of US$1.75b Q3 revenue and net income of US$506m. The trailing profit margin has narrowed to 31.7% from 41.6%. The UNITY failure in Sjögren’s and extra Forte related spending pushed combined R&D and SG&A to US$1.1b this quarter. That mix supports the concern that expansion requires heavy reinvestment with real clinical setbacks along the way.
The price and this Narrative do not agree. → Uncover what this Narrative says argenx is actually worth.
Hunt For Underpriced Earnings Power
argenx just showed how a profitable autoimmune story can spark questions about balancing growth and margin. The real opportunity is finding stocks that could be undervalued before the market fully recognizes their earnings power.
- Company 1 - 34% below our estimate - targets complex manufacturing work for regulated customers as new contracts shift from awards to production.
- Company 2 - 44% below our estimate - sells treatment planning software compatible with rival radiation systems as hospitals adopt subscription models and AI supported workflows.
- Company 3 - 45% below our estimate - builds a branded therapy portfolio as tighter working capital and pipeline additions support free cash flow resilience.
Three companies from the same screener. Open all 191 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com